Seguendo questo link salti il contenuto della pagina e vai direttamente alla Mappa del sito a fondo pagina
(IT) EN
Sei in:
Personale dell'ISS

Stefano Vella

Dirigente di ricerca
+39 06 4990 6016
Viale Regina Elena 299
00161 - Roma (I)
stefano.vella@iss.it


Curriculum vitae

Direttore di Centro GLOB - Centro nazionale salute globale

Note Biografiche

Laureato in Medicina e Chirurgia, Università di Roma (1977);
Specializzato in Malattie Infettive, Università di Roma (1982);
Specializzato in Medicina Interna, Università di Roma (1988).


Incarichi

1977-1981 Medico Interno, Istituto di III Clinica Medica, Università di Roma La Sapienza
1981-1982 Associate Scientist, The Wistar Institute,
University of Pennsylvania, USA [Dr. Carlo Croce]
1982-1991 Ricercatore, Istituto di Medicina Interna, Policlinico
Umberto I, Università di Roma La Sapienza;
1992 - Dirigente di Ricerca, Istituto Superiore di Sanità, Roma
1994-1998 Direttore Reparto Infezioni da Retrovirus, Laboratorio di Virologia, Istituto Superiore di Sanità
1996 - Responsabile Scientifico del Progetto Patologia, clinica e terapia dell'Infezione da HIV;Programma Nazionale di Ricerca sull'AIDS
1997- Docente Universitario in Farmacologia Antivirale, Università di Urbino
1994-1995 Docente Universitario in Terapia delle Malattie Infettive, Università di Roma "Tor Vergata"
1995-1998 Docente Universitario in Terapia delle Malattie Infettive, Università di Sassari
2002-2003 Docente Universitario in Terapia delle Malattie Infettive, Università di Genova


Attività di Ricerca

Studi clinici randomizzati e controllati ITALIA-USA, ACTG 384 e ACTG 388. Studio clinico randomizzato e controllato internazionale INITIO. Studio ISS-PART sulla terapia anti-HIV intermittente. Progetto Multidisciplinare sulla Terapia delle Malattie da Virus (Ministero della Salute, Ricerca Finalizzata 2000). Progetti di Ricerca sulla trasmissione materno-fetale, studi clinici randomizzati PETRA e SIMBA (Uganda e Rwanda). L'accesso alle terapie in Monzambico (collaborazione con la Comunità di S. Egidio).


Progetti di ricerca

1995- Comitato di Revisione Internazionale dei Progetti di Ricerca sull'HIV/AIDS, NIAID, National Institutes of Health, USA
1996- Esperto Internazionale dell'Ufficio Federale Svizzero di Sanità Pubblica
1996- Steering Committee, EUROSIDA
2000- ACTG Research Agenda Committee (RAC), NIAID, NIH
2001- Panel Internazionale di Revisione dei Progetti di Ricerca dell'ANRS (Agenzia Francese per la Ricerca sull'AIDS)
2001- Comitato di Revisione della ricerca clinica, Canadian Institute of Health Research (CIHR)
2001-2002 Steering Committee, WHO Program for the Global Monitoring of Antiretroviral Resistance (2001-2002)
2002- Gruppo di supporto tecnico-scientifico del Global Fund per la lotta all'AIDS, Tubercolosi e Malaria


Incarichi Istituzionali

1992- Commisione Nazionale AIDS - Ministero della Sanità
1995 Commissione Sperimentazione Clinica - Ministero della Sanità
1996 Commissione del National Institutes of Health (USA) per la Definizione delle Linee Guida USA di Terapia dell'infezione da HIV
1996- Commissione IAS-USA sulla Terapia Antiretrovirale per l'infezione da HIV
1997-2001 Ad-Hoc Working Group on Antiretroviral Medicinal Products (EMEA), Londra
1998- Commissione IAS-USA sulla Resistenza ai Farmaci Antiretrovirali
1999-2002 Commissione Internazione del WHO sulla Terapia Antiretrovirale
2000 Meeting Consultivo sulla Terapia Antiretrovirale in Paesi in via di Sviluppo (WHO)
2000 Meeting Consultivo Internazionale sul Monitoraggio Globale sulla Resistenza Antiretrovirale (WHO)
2000- Program Coordinating Board (PCB), UNAIDS
2001 Delegazione italiana, United Nations General Assembly, Sessione Speciale sull'AIDS (UNGASS - New York, giugno 23-25)
2001- Comitato Etico, Istituto Superiore di Sanità
2003- WHO Senior Scientific Adviser


Membership

Facente parte dell'Editorial Boards delle seguenti Riviste Scientifiche:
1996-2001 AIDS
1996- Antiviral Therapy
1995- AIDS Clinical Care
1999- Journal of Clinical Trials
2000- Journal of AIDS
2000- Journal of HIV Medicine
1982- Redattore dell'Enciclopedia Medica Italiana (UTET, Torino)
- Reviewer per numerose riviste internazionali, tra cui Lancet, Science, Journal of Infectious Diseases, AIDS, Journal of AIDS.
- Revisore ufficiale dell'Edizione italiana del New England Journal of Medicine.


Brevetti





Pubblicazioni

  1. Giuliano M, Guidotti G, Andreotti M, Pirillo MF, Villani P, Liotta G, Marazzi MC, Mancini MG, Cusato M, Germano P, Loureiro S, Ceffa S, Regazzi M, Vella S, Palombi L. Triple antiretroviral prophylaxis administered during pregnancy and after delivery significantly reduces breast milk viral load. A study within the drug resource enhancement program. Journal of acquired immune deficiency syndromes 2007;44(3):286-291.
  2. Nicastri E, Leone S, Angeletti C, Palmisano L, Sarmati L, Chiesi A, Geraci A, Vella S, Narciso P, Corpolongo A, Andreoni M. Sex issues in HIV-1-infected persons during highly active antiretroviral therapy: a systematic review. Journal of antimicrobial chemotherapy 2007;60(4):724-732.
  3. Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA. Treatment for adult HIV infection: 2006 recommendations of the international AIDS Society-USA Panel. JAMA 2006;296(7):827-843.
  4. Panei P, Knellwolf AL, Arcieri R, Vella S. Absence of unfavorable effect of atomoxetine on growth in pediatric patients is still not yet demonstrated [letter]. Pediatrics 2006;117(2):587-588.
  5. Bona R, Andreotti M, Buffa V, Leone P, Galluzzo CM, Amici R, Palmisano L, Mancini MG, Michelini Z, Di Santo R, Costi R, Roux A, Pommier Y, Marchand C, Vella S, Cara A. Development of human immunodeficiency virus vector-based, single-cycle assay for evaluation of anti-integrase compounds. Antimicrobial agents and chemotherapy 2006;50(10):3407-3417.
  6. Vella S, Palmisano L. The global status of resistance to antiretroviral drugs. Clinical infectious diseases 2005;41(Suppl 4):S239-S246.
  7. Palmisano L, Giuliano M, Nicastri E, Pirillo MF, Andreotti M, Galluzzo CM, Bucciardini R, Fragola V, Andreoni M, Vella S. Residual viraemia in subjects with chronic HIV infection and viral load < 50 copies/ml: the impact of highly active antiretroviral therapy. AIDS 2005;19(16):1843-1847.
  8. Nicastri E, Angeletti C, Palmisano L, Sarmati L, Chiesi A, Geraci A, Andreoni M, Vella S, Italian antiretroviral treatment group (IATG). Gender differences in clinical progression of HIV-1 infected persons during long-term highly active antiretroviral therapy. AIDS 2005;19(6):577-583.
  9. Nicastri E, Chiesi A, Angeletti C, Sarmati L, Palmisano L, Geraci A, Andreoni M, Vella S, Italian antiretroviral treatment group (IATG). Clinical outcome after 4 years follow-up in HIV-seropositive subjects with incomplete virologic or immunologic response to HAART. Journal of medical virology 2005;76(2):153-160.
  10. d'Arminio Monforte A, Cinque P, Mocroft A, Goebel F, Antunes F, Katlama C, Justesen US, Vella S, Kirk O, Lundgren JD, EuroSIDA Study Group. Changing incidence of central nervous system diseases in the EuroSIDA cohort. Annals of neurology 2004;55(3):320-328.
  11. Yeni PG, Hammer SM, Hirsch MS, Saag MS, Schechter M, Carpenter CC, Fischl MA, Gatell JM, Gazzard BG, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Schooley RT, Thompson MA, Vella S, Volberding PA. Treatment for adult HIV infection: 2004 recommendations of the international AIDS Society-USA panel. JAMA 2004;292(2):251-265.
  12. Dragsted UB, Mocroft A, Vella S, Viard JP, Hansen AE, Panos G, Mercey D, Machala L, Horban A, Lundgren JD, EuroSIDA Study Group. Predictors of immunological failure after initial response to highly active antiretroviral therapy in HIV-1 infected adults: a EuroSIDA study. Journal of infectious diseases 2004;190(1):148-155.
  13. Vandamme A, Sönnerborg A, Ait-Khaled M, Albert J, Asjo B, Bacheler L, Banhegyi D, Boucher CAB, Brun-Vézinet F, Camacho RJ, Clevenbergh P, Clumeck N, Dedes N, De Luca A, Doerr HW, Faudon J, Gatti G, Gerstoft J, Hall WW, Hatzakis A, Hellmann N, Horban A, Lundgren JD, Kempf D, Miller M, Miller V, Myers TW, Nielsen C, Opravil M, Palmisano L, Perno CF, Phillips AN, Pillay D, Pumarola T, Ruiz L, Salminen M, Schapiro J, Schmidt B, Schmit J, Schuurman R, Shulse E, Soriano V, Staszewski S, Vella S, Youle M, Ziermann R, Perrin L. Updated European recommendations for the clinical use of HIV drug resistance testing. Antiviral therapy 2004;9(6):829-848.
  14. Mocroft A, Gatell JM, Reiss P, Ledergerber B, Kirk O, Vella S, Blaxhult A, Phillips AN, Lundgren JD, EuroSIDA Study Group. Causes of death in HIV infection: the key determinant to define the clinical response to anti-HIV therapy. AIDS 2004;18(17):2333-2337.
  15. Giuliano M, Palmisano L, Galluzzo CM, Amici R, Germinario EAP, Okong P, Namaganda PK, Mmirro F, Magoni M, Vella S. Selection of resistance mutations in pregnant women receiving zidovudine and lamivudine to prevent HIV perinatal transmission. AIDS 2003;17(10):1570-1572.
  16. Vella S, Palmisano L. Beyond lipodystrophy: will toxicity issues ever outweigh the benefits of HAART? [editorial]. Journal of HIV therapy 2003;8(2):27-28.
  17. Palmisano L, Giuliano M, Galluzzo CM, Amici R, Bucciardini R, Vella S. Resistance mutations during intermittent antiretroviral therapy: does PBMC genotyping before treatment interruption help predict their occurrence? [abstract]. Antiviral therapy 2003;8(3):S166.
  18. Florence E, Lundgren JD, Dreezen C, Fisher M, Kirk O, Blaxhult A, Panos G, Katlama C, Vella S, Phillips AN, EuroSIDA Study Group. Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. HIV medicine 2003;4(3):255-262.
  19. Fischl MA, Ribaudo HJ, Collier AC, Erice A, Giuliano M, Dehlinger M, Eron JJ, Saag MS, Hammer SM, Vella S, Morse GD, Feinberg JE, AIDS Clinical Trials Group 388 Study. A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease. Journal of infectious diseases 2003;188(5):625-634.
  20. Sarmati L, Nicastri E, Uccella I, D'Ettorre G, Parisi SG, Palmisano L, Galluzzo CM, Concia E, Vullo V, Vella S, Andreoni M. Drug-associated resistance mutations in plasma and peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected patients from whom highly active antiretroviral therapy is failing. Journal of clinical microbiology 2003;41(4):1760-1762.
  21. Cozzi Lepri A, Philips AN, Miller V, Katlama C, Ledergerber B, Vella S, Weber J, Bruun JN, Kirk O, Clotet B, Lundgren JD. Changes in viral load in people with virological failure who remain on the same HAART regimen. Antiviral therapy 2003;8:127-136.
  22. Vella S. Future treatment perspectives. JAIDS-Journal of acquired immune deficiency syndromes 2003;34(Suppl 1):S95-S100.
  23. Di Fabio S, Van Roey J, Giannini G, Van den Mooter G, Spada M, Binelli A, Pirillo MF, Germinario EAP, Belardelli F, De Bethune M, Vella S. Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor TMC120 in a gel formulation. AIDS 2003;17(11):1597-1604.
  24. Matarrese P, Gambardella L, Cassone A, Vella S, Cauda R, Malorni V. Mitochondrial membrane hyperpolarization Hijacks activated T lymphocytes toward the apoptotic-prone phenotype: homeostatic mechanisms of HIV protease inhibitors. Journal of immunology 2003;170(12):6006-6015.
  25. Vella S. New antiretroviral drugs. In: Mandarino G, Marella AM, ed. International symposium Non conventional unexpected benefits of protease inhibitors in HAART. Istituto Superiore di Sanità. Rome, October 31, 2003. Abstract book. Roma: Istituto Superiore di Sanità; 2003. (ISTISAN Congressi 03/C4). p.7.
  26. Matarrese P, Gambardella L, Cassone A, Cauda R, Vella S, Malorni V. HIV-protease inhibitors modulate apoptotic proneness of activated T lymphocytes via a target effects on their mitochondria. In: Mandarino G, Marella AM, ed. International symposium Non conventional unexpected benefits of protease inhibitors in HAART. Istituto Superiore di Sanità. Rome, October 31, 2003. Abstract book. Roma: Istituto Superiore di Sanità; 2003. (ISTISAN Congressi 03/C4). p.22.
  27. Robbins GK, De Gruttola V, Shafer RW, Smeaton LM, Snyder SW, Pettinelli C, Dubè MP, Fischl MA, Pollard RB, Dalapenha R, Gedeon L, van der Horst C, Murphy RL, Becker MI, D'Aquila RT, Vella S, Merigan TC, Hirsch MS, AIDS Clinical Trials Group 384 Team. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. New England journal of medicine 2003;349(24):2293-2303.
  28. Shafer RW, Smeaton LM, Robbins GK, De Gruttola V, Snyder SW, D'Aquila RT, Johnson VA, Morse GD, Nokta MA, Martinez AI, Gripshover BM, Kaul P, Haubrich R, Swingle M, McCarty DS, Vella S, Hirsch MS, Merigan TC, AIDS Clinical Trials Group 384 Team. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. New England journal of medicine 2003;349(24):2304-2315.
  29. Nicastri E, Sarmati L, D'Ettorre G, Parisi SG, Palmisano L, Galluzzo CM, Montano M, Uccella I, Amici R, Gatti F, Vullo V, Concia E, Vella S, Andreoni M. High prevalence of M184 mutation among patients with viroimmunologic discordant responses to highly active antiretroviral therapy and outcomes after change of therapy guided by genotypic analysis. Journal of clinical microbiology 2003;41(7):3007-3012.
  30. Vella S, Giuliano M, Palmisano L, Bucciardini R, Andreotti M, Arcieri P, Fragola V, Galluzzo CM, Weimer LE, Pirillo MF, Amici R, Germinario EAP, Palio E. ISS-PART: A prospective, randomized, multi-center clinical trial of intermittent therapy in HIV+ subjects with persistent suppression of viral replications. In: 10. Conference on Retroviruses and Opportunistic Infections. Abstracts; February 10-14, 2003; Boston. 2003. p.81.
  31. Hart S, Shafer RW, Tanuri A, Soares M, Brun-Vézinet F, Grossman Z, Rudich H, Ram D, Richards N, Mugyenyi P, Arts E, Palmisano L, Vella S, De Felici A, Kantor R. Global mapping of HIV-1 drug resistance patterns. In: 10. Conference on Retroviruses and Opportunistic Infections. Abstracts; February 10-14, 2003; Boston. 2003. p.281.
  32. Matarrese P, Gambardella L, Cauda R, Mormone E, Ascione B, Vona R, Vella S, Malorni V. On homeostatic mechanisms of HIV-protease inhibitors: their role in regulating mitochondrial activity and apoptosis proneness in activited T lymphocytes. In: 11. Euroconference on Apoptosis Cell Death Under the Three Towers. Abstracts; October 25-28, 2003; Ghent; 2003.
  33. Palmisano L, Giuliano M, Galluzzo CM, Amici R, Andreotti M, Germinario EAP, Bucciardini R, Vella S. Presence of resistance mutations in PBMC of subjects with persistent suppression of viral replication during their first-line haart. In: 2. IAS Conference on HIV Pathogenesis and Treatment. Abstracts; July 13-16, 2003; Paris. 2003. p.S416.
  34. Floridia M, Fragola V, Galluzzo CM, Giannini G, Pirillo MF, Andreotti M, Tomino C, Vella S, ISS-IP1 Study Group. HIV-related morbidity and mortality in patients starting protease inhibitors in very advanced HIV disease (CD4 count of <50cells/microL: an analysis of 338 clinical events from a randomized clinical trial. HIV medicine 2002;3(2):75-84.
  35. Mothanje BL, Rutella S, Leone G, Larocca LM, Vella S, Cauda R. In vitro and in vivo modulation of MDR1/P-glycoprotein in HIV-infected patients administered highly active antiretroviral therapy and liposomal doxorubicin. Journal of acquired immune deficiency syndromes 2002;30(4):369-378.
  36. Vella S. L'interruzione strutturata di terapia antiretrovirale (STI). ReAd files. Resistenza e adesione alle terapie nella cura dell'AIDS 2002;1(2):1.
  37. Vella S. New perspectives in antiretroviral therapy of HIV infection. In: Cossarizza A, Kaplan D, ed. Cellular aspects of HIV infection New York: John Wiley & Sons Inc; 2002. p.423-437.
  38. Giuliano M, Galluzzo T, Amici R, Declich S, Okong P, Namaganda PK, Magoni M, Palmisano L, Bray D, Vella S. Selection of resistance mutations in pregnant women receiving short-course antiretroviral regimens with ZDV and 3TC to prevent perinatal transmission (PETRA Study). In: 9. Conference on Retroviruses and Opportunistic Infections. Abstracts; February 24-28, 2002; Seattle. 2002. p.343.
  39. Hogg R, Cahn P, Katabira ET, Lange JMA, Samuel N, O'Shaughnessy M, Vella S, Wainberg MA, Montaner JS. Time to act: global apathy towards HIV/AIDS is a crime against humanity. Lancet 2002;360(9347):1710-1711.
  40. ADHOC International steering committee. A randomized placebo-controlled trial of adefovir dipivoxil in advanced HIV infection: the ADHOC trial. HIV medicine 2002;3(4):229-238.
  41. Vella S. Access to HIV care and treatment in the developing world: responding to the objections. AIDS clinical care 2002;14(3):19-26.
  42. Vella S. Antiretroviral drug resistance and HIV/AIDS in the developing world. Journal of HIV therapy 2002;7(3):53-55.
  43. Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S, Volberding PA. Antiretroviral treatment for adult HIV infection in 2002. Updated recommendations of the international AIDS society-USA panel. JAMA 2002;288(2):222-235.
  44. Miller V, Philips AN, Clotet B, Mocroft A, Ledergerber B, Kirk O, Ormaasen V, Gargalianos P, Vella S, Lundgren JD, EuroSIDA Study Group. Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell count. Journal of infectious diseases 2002;186(2):189-197.
  45. D'Ettorre G, Forcina G, Andreotti M, Sarmati L, Palmisano L, Galluzzo CM, Nicastri E, Mastroianni CM, Vullo V, Vella S, Andreoni M. Discordant response to antiretroviral therapy: HIV isolation, genotypic mutations, T-cell proliferation and cytokine production. AIDS 2002;16(14):1877-1885.
  46. Havlir D, Vella S, Hammer SM. The global HIV drug resistance surveillance program: a partnership between WHO and IAS. AIDS 2002;16(10):7-9.
  47. Grelli S, Di Traglia L, Matteucci C, Lichtner M, Vullo V, Di Sora F, Lauria F, Montella F, Favalli C, Vella S, Macchi B, Mastino A. Changes in apoptosis after interruption of potent antiretroviral therapy in patients with maximal HIV-1-RNA suppression. AIDS 2001;15(9):1178-1181.
  48. Conway B, Wainberg MA, Hall D, Harris M, Reiss P, Cooper DA, Vella S, Curry R, Robinson P, Lange JMA, Montaner JS. Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine. AIDS 2001;15(10):1269-1274.
  49. Matarrese P, Testa U, Cauda R, Vella S, Gambardella L, Malorni V. Expression of P-170 glycoprotein sensitizes lymphoblastoid CEM cells to mitochondria-mediated apoptosis. Biochemical journal 2001;355(Pt 3):587-595.
  50. Vella S, Palmisano L. Facing an emerging threat: the spread of HIV resistance [editorial]. Journal of HIV therapy 2001;6(3):49-50.
  51. Mothanje BL, Rutella S, Leone G, Vella S, Cauda R. HIV-Protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV - positive patients receiving HAART. Journal of acquired immune deficiency syndromes 2001;27(4):321-330.
  52. Viganò A, Pinti M, Nasi M, Moretti L, Balli F, Mussini C, Bricalli D, Sala N, Bugarini R, Vella S, Principi N, Cossarizza A. Markers of cell death-activation in lymphocytes of vertically HIV-infected children naive to highly active antiretroviral therapy: the role of age. Journal of allergy and clinical immunology 2001;108(3):439-445.
  53. Hale P, Makgoba MW, Merson MH, Quinn TC, Richman DD, Vella S, Wabwire-Mangen F, Wain-Hobson S, Weiss RA. Mission now possible for AIDS fund. Nature 2001;412(6844):271-272.
  54. Stellbrink HJ, Hawkins DA, Clumeck N, Cooper DA, Myers Jr R, Delfraissy J, Gill JM, Ramirez-Ronda C, Vella S, Salgo M, Bragman K. Randomised, multicentre phase III study of saquinavir plus zidovudine plus zalcitabine in previously untreated or minimally pretreated HIV-infected patients. Clinical drug investigation 2001;20(5):295-307.
  55. Hale P, Makgoba MW, Merson MH, Quinn TC, Richman DD, Vella S, Wabwire-Mangen F, Wain-Hobson S, Weiss RA. Success hinges on support for treatment. Nature 2001;412(6844):272.
  56. Di Fabio S, Giannini G, Lapenta C, Spada M, Binelli A, Germinario EAP, Sestili P, Belardelli F, Proietti E, Vella S. Vaginal transmission of HIV-1 in hu-SCID mice: a new model for the evaluation of vaginal microbicides. AIDS 2001;15(17):2231-2238.
  57. Veldkamp AI, Weverling GJ, Lange JMA, Montaner JS, Reiss P, Cooper DA, Vella S, Hall D, Beijnen JH, Hoetelmans RM. High exposure to neviparine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS 2001;15(9):1089-1095.
  58. Kallings LO, Vella S. Access to HIV/AIDS care and treatment in the South of the world. AIDS 2001;15(7):1-3.
  59. Hirsch MS, Brun-Vézinet F, D'Aquila RT, Hammer SM, Johnson VA, Kuritzkes DR, Loveday C, Mellors JW, Clotet B, Conway B, Demeter LM, Vella S, Jacobsen DM, Richman DD. Antiretroviral drug resistance in adult HIV-1 infection. Recommendations of an international AIDS Society-USA panel. JAMA 2000;283(18):2417-2426.
  60. Hirsch MS, Brun-Vézinet F, D'Aquila RT, Hammer SM, Johnson VA, Kuritzkes DR, Loveday C, Mellors JW, Clotet B, Conway B, Demeter LM, Vella S, Jacobsen DM, Richman DD. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an international AIDS society-USA panel. JAMA 2000;283(18):2417-2426.

Note legali


© - Istituto Superiore di Sanità Viale Regina Elena 299 - 00161 - Roma (I)
Partita I.V.A. 03657731000 - C.F. 80211730587 - Note legali

ISS Home

Informiamo i visitatori, in virtù della individuazione delle modalità semplificate per l'informativa e l'acquisizione del consenso per l'uso dei cookie - 8 maggio 2014 (Pubblicato sulla Gazzetta Ufficiale n. 126 del 3 giugno 2014), che questo sito utilizza direttamente solo cookie tecnici.[Ho letto]